The HER3-targeting ADC patritumab deruxtecan (HER3-DXd, U3-1402) demonstrated clinical activity against EGFR-TKI-resistant NSCLC in the HERTHENA-Lung01 study, which provides a strategy to treat osimertinib-resistant NSCLC [221]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.